期刊文献+

帕金森病患者血清中sRAGE水平及其临床意义 被引量:1

sRAGE serum levels in Parkinson disease and its clinical significance
原文传递
导出
摘要 目的 检测帕金森病(PD)患者外周血中可溶性晚期糖基化终产物受体(sRAGE)的含量变化,并初步探讨其与PD的关系.方法 采用双抗体夹心ELISA法测定100例PD组患者与100例对照组(同期体检健康者)血清中sRAGE的含量并进行比较.结果 PD组血清sRAGE水平(767.44±18.21) pg/ml低于健康对照组(792.78±41.48) pg/ml,差异有统计学意义(t=-5.59,P<0.01).PD患者不同严重程度组间血清sRAGE水平,由轻到重sRAGE水平呈下降趋势,但组间差异无统计学意义(F=1.28,P>0.05).相同年龄段间PD组与健康对照组血中sRAGE表达水平比较,50-60岁和60-70岁年龄段两组间差异有统计意义(t分别为4.65,3.07;P<0.01).结论 PD组血清中sRAGE水平明显低于健康对照组,特别在50-70岁年龄段,且其水平与PD严重程度无明显相关性,推测sRAGE可能通过竞争结合晚期糖基化终产物受体(RAGE)的配体减弱后者的病理作用,可能在PD中起潜在保护作用.
出处 《神经疾病与精神卫生》 2014年第2期191-193,共3页 Journal of Neuroscience and Mental Health
基金 黑龙江省教育厅科学技术研究项目(12521230)
关键词 帕金森病 可溶性晚期糖基化终产物受体(sRAGE) Parkinson disease Soluble receptor for advanced glycation end products (sRAGE)Enzyme linked immunosorbent assay (ELISA)
  • 相关文献

参考文献13

  • 1蒋雨平,王坚,丁正同,邬剑军,陈嬿.原发性帕金森病的诊断标准(2005年)[J].中国临床神经科学,2006,14(1):40-40. 被引量:155
  • 2Yang SJ, Kim S, Hwang SY, et al. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography [J]. Atherosclerosis, 2012,220 (2) : 402 - 406.
  • 3Sakurai S,Yonekura H, Yamamoto Y, et al. Identification of a novel AGE-capturable soluble variant of the RAGE in hu- man sera[J]. Inter Con Ser, 2002,1254 : 163- 167.
  • 4Bianchi R, Giambanco I, Donato R. S100B/RAGE-depend- ent activation of microglia via NF- kappaB and AP- 1 Co- regulation of COX- 2 expression by S100B, IL- 1beta and TNF-alpha[J]. Neurobiol Aing,2010,31(4) :665-677.
  • 5Nakamura K,Yamagishi S, Nakaura Y, et al. Telmisartan in hibits expression of a receptor for advanced glycation end prod- ucts in giotensinexp sed endothelial cells and decreases serum levels of soluble rage in patients with essensial hypertension [J]. Microvasc Res,2005,70(3) : 137- 141.
  • 6Hzecka J. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis [J]. Acta Neurol Scand,2009,120(2):119-122.
  • 7吕萍,许芳,赵广健,徐春晶,徐菲,姚丽芬.阿尔茨海默病患者血浆可溶性晚期糖基化终产物受体表达水平[J].神经疾病与精神卫生,2012,12(2):182-184. 被引量:1
  • 8Ma L, Nicholson LF. Expression of the receptor for advanced glyeation end products in Huntington's disease caudate nucleus [J] . Brain Res,2004,1018(1) :10-17.
  • 9Sasaki N, Takeuchi M, Chowei H, et al. Advanced glycation end products and their receptor(RAGE) in the brain of pa- tients with Creutzfeldt-Jakob disease with prion plaques[J]. Neurosci lett,2002,326(2) :117-120.
  • 10Casula M, lyer AM, Spliet WG, et al. Toll-like receptor sig- naling in amyotrophic lateral sclerosis cord tissue[J] . Neuro- science, 2011,179 : 233-243.

二级参考文献15

  • 1Geroldi D,Falcone C, Emanuele E. Soluble receptor for ad- vanced glycation end products: from disease marker to potential therapeutic target[J]. Curr Med Chem, 2006, 13 (17): 1 971 - 1 978.
  • 2Lue LF,Walker DG,Jacobson S, et al. Receptor for advanced glycation end products: its role in Alzheimer's disease and oth- er neurological diseases[J]. Future Neurol, 2009,4 ( 2 ) : 167 - 177.
  • 3Schmidt AM,Yah SD,Yan SF,et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflam- matory responses[J]. J Clin Invest,2001,108(7):949-955.
  • 4Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP- 1,and amyloid-beta protein in ALzheimer's disease[J]. Acta Neuropathol, 2006,112 (4) :405 - 415.
  • 5Lue LF,Walker DG,Brachova L,et al. Involvement f microgli- al receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism[J]. Exp Neurol, 2001,171 (1) :29- 45.
  • 6Origlia N,Righi M,Capsoni S. Receptor for advanced glyeation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid- β- mediated cortical synaptic dysfunction[J]. J Neurosei, 2008,28 (13) : 3 521 - 3 530.
  • 7Sheng TG,Jones RA, Zhou XQ, et al. Interkeukin- 1 promo- tion of MAPK-p38 over-expression in experimental animals and in Alzheimer's disease: potential significance for taupro- t einphosphorylation[J]. Neuroehem Int, 2001,39 ( 5/6) : 341.
  • 8Lue LF, Walker DG,Jacobson S, et al. Receptor for advanced glycation end products: its role in Alzheimer's disease and oth- er neurological diseases[J]. Future Neurol,2009,4(2): 167- 177.
  • 9Emanuele E, D'AngeloA, Tomaino C,et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia [J]. Arch Neurol, 2005,62(11)zl 734-1 736.
  • 10Cho HJ,Son SM,Jin SM,et al. RAGE regulates BACE1 and Aβgeneration via NFAT1 activation in Alzheimer's disease an- imal model[J]. FASEB J,2009,23(8) :2 639-2 649.

共引文献175

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部